Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Germ cell tumours of childhood and adolescence (extracranial and CNS), drawn from the whole corpus: 4 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Whether carboplatin can fully replace cisplatin without losing cures in standard-risk disease; AGCT1531 is the answer trial.
Relapsed and platinum-refractory disease, especially mediastinal and CNS non-germinomatous tumours, where high-dose chemotherapy is the only option.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Long-term hearing, kidney, fertility and cardiovascular effects; otoprotection, fertility preservation and survivorship clinics address them.
Harmonising paediatric, adolescent and adult protocols so that a 17-year-old and a 19-year-old receive the same evidence-based care.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 8 changes by month →When this page itself was last checked or edited.
Three-year progression-free survival 87.
SIOPEL 6 (NEJM 2018) and ACCL0431 show reduced cisplatin ototoxicity; FDA approval 2022.
Joint COG/CCLG trial of active surveillance and carboplatin versus cisplatin.
Frazier and colleagues (JCO) combine COG and CCLG data to define shared risk groups.
POG/CCG intergroup studies show surgery alone is safe for low-stage disease.